Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H9Cl3N4O2 |
Molecular Weight | 407.638 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(C=C1)C(C#N)C2=C(Cl)C=C(C=C2Cl)N3N=CC(=O)NC3=O
InChI
InChIKey=ZSZFUDFOPOMEET-UHFFFAOYSA-N
InChI=1S/C17H9Cl3N4O2/c18-10-3-1-9(2-4-10)12(7-21)16-13(19)5-11(6-14(16)20)24-17(26)23-15(25)8-22-24/h1-6,8,12H,(H,23,25,26)
Molecular Formula | C17H9Cl3N4O2 |
Molecular Weight | 407.638 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=875c461a-e0db-4478-9006-7bd1d006ed3a
Curator's Comment: description was created based on several sources, including, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=875c461a-e0db-4478-9006-7bd1d006ed3a
Diclazuril is a main component of veterinary drugs used for the treatment of coccidiosis (chickens, turkeys, rabbits, etc) and equine protozoal myeloencephalitis (horses). When used for the treatment of coccidiosis, it acts by causing the degeneration of schizonts and gamonts. While in the animals affected by protozoal myeloencephalitis the drug is believed to inhibit merozoite production. In vivo experiments on horses have shown that the drug may cross the blood brain barrier.
CNS Activity
Sources: http://thomastobin.com/archive/240%20-%20Detection,%20Quantification%20and%20pharmacokinetics%20of%20Dic.pdf
Curator's Comment: The drug was shown to cross the BBB in horses.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Differentiation during parasite development |
|||
Target ID: Merozoite production |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | CLINACOX Approved UseFor the prevention of coccidiosis in animals. Launch Date1999 |
|||
Curative | PROTAZIL Approved UseFor the treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona. Launch Date2007 |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model. | 1991 Nov-Dec |
|
Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. | 1993 Mar |
|
Activity of diclazuril against Toxoplasma gondii in cultured cells and mice. | 1994 Apr |
|
Efficacy of diclazuril in comparison with chemical and ionophorous anticoccidials against Eimeria spp. in broiler chickens in floor pens. | 2001 Apr |
|
Activity of toltrazuril and diclazuril against Isospora species in kittens and puppies. | 2001 Apr 21 |
|
Resistance to anticoccidial drugs of Dutch avian Eimeria spp. field isolates originating from 1996, 1999 and 2001. | 2003 Aug |
|
The efficacy and economic benefits of Supercox, a live anticoccidial vaccine in a commercial trial in broiler chickens in China. | 2006 Nov 30 |
|
Higher incidence of Eimeria spp. field isolates sensitive for diclazuril and monensin associated with the use of live coccidiosis vaccination with paracox-5 in broiler farms. | 2006 Sep |
|
Increased level of Eimeria sensitivity to diclazuril after using a live coccidial vaccine. | 2006 Sep |
|
New therapeutic approaches for equine protozoal myeloencephalitis: pharmacokinetics of diclazuril sodium salts in horses. | 2006 Spring |
|
Efficacy of various anticoccidials against experimental porcine neonatal isosporosis. | 2007 Jan |
|
Efficacy of some anticoccidial drugs for treating coccidial enteritis of the common carp caused by Goussia carpelli (Apicomplexa: Eimeriidae). | 2007 Mar |
|
Use of antigen mimics to produce specific antibodies to anti-coccidial drugs. | 2007 May 31 |
|
The effect of a metaphylactic treatment with diclazuril (Vecoxan) on the oocyst excretion and growth performance of calves exposed to a natural Eimeria infection. | 2007 Nov 10 |
|
Effect of subcutaneously administered diclazuril on the output of Eimeria species oocysts by experimentally infected rabbits. | 2008 Feb 2 |
|
Assessing the effect of diclazuril on the intestinal absorptive capacity of broilers infected with experimental coccidiosis, using d-xylose absorption test. | 2008 Jun |
|
Comparison of three adjuvants used to produce polyclonal antibodies to veterinary drugs. | 2008 Mar 15 |
|
Efficacy of toltrazuril (Baycox 5% suspension) in natural infections with pathogenic Eimeria spp. in housed lambs. | 2009 Apr |
|
Study of the comparative efficacy of toltrazuril and diclazuril against ovine coccidiosis in housed lambs. | 2009 Aug |
|
Genotype comparison of sorbitol-negative Escherichia coli isolates from healthy broiler chickens from different commercial farms. | 2009 Jul |
|
Dietary supplementation of mannan-oligosaccharide enhances neonatal immune responses in chickens during natural exposure to Eimeria spp. | 2009 Mar 19 |
|
Fast liquid chromatography/multiple-stage mass spectrometry of coccidiostats. | 2009 May |
|
Validation of a multi-residue liquid chromatography-tandem mass spectrometry confirmatory method for 10 anticoccidials in eggs according to Commission Decision 2002/657/EC. | 2009 Nov 13 |
|
Actin-depolymerizing factor of second-generation merozoite in Eimeria tenella: clone, prokaryotic expression, and diclazuril-induced mRNA expression. | 2010 Feb |
|
Histomorphometry and macroscopic intestinal lesions in broilers infected with Eimeria acervulina. | 2010 Mar 25 |
|
Livestock drugs and disease: the fatal combination behind breeding failure in endangered bearded vultures. | 2010 Nov 30 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/scripts/animaldrugsatfda/details.cfm?dn=141-268
Coccidiosis: Mix 200 gram of Clinacox 0.5% premix per ton of complete feed. Equine protozoal myeloencephalitis: 1 milligram per kilogram of body weight in the daily grain ration for 28 days
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:29:59 GMT 2025
by
admin
on
Mon Mar 31 19:29:59 GMT 2025
|
Record UNII |
K110K1B1VE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.606
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
||
|
CFR |
21 CFR 558.198
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
||
|
WHO-VATC |
QP51AJ03
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
||
|
NCI_THESAURUS |
C277
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
||
|
CFR |
21 CFR 556.185
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
K110K1B1VE
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
K110K1B1VE
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
1368201
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | RxNorm | ||
|
1188560
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
456389
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
m4360
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL284733
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
5971
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
Y-61
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
100000082936
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
101831-37-2
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
C76418
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
DB11398
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
DICLAZURIL
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
C057884
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
SUB07091MIG
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
759642
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY | |||
|
DTXSID4046787
Created by
admin on Mon Mar 31 19:29:59 GMT 2025 , Edited by admin on Mon Mar 31 19:29:59 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity-0.25% peak area.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4; Specific limit not given. Any other impurity-0.25% peak area.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
Specific limit is not given. Any other impurity - 0.25% peak area.
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |